ASO VISUAL ABSTRACT

ASO Visual Abstract: *SLC7A9* as a Potential Biomarker for Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma

Hayato Baba, MD^{1,2}, Mitsuro Kanda, MD, PhD, FACS², Koichi Sawaki, MD, PhD², Shunsuke Nakamura, MD, PhD², Sei Ueda, MD^{2,3,4}, Dai Shimizu, MD, PhD², Masahiko Koike, MD, PhD², Yasuhiro Kodera, MD, PhD, FACS², and Tsutomu Fujii, MD, PhD, FACS¹

¹Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan;

²Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan;

³Department of Maxillofacial Surgery, School of Dentistry, Aichi-gakuin University Graduate School of Medicine, Nagoya, Japan; ⁴Department of Surgery, School of Dentistry, Aichi-gakuin University Graduate School of Medicine, Nagoya, Japan

The authors first showed the potential role of solute carrier family 7, member 9 (*SLC7A9*) as an oncogene in esophageal squamous cell carcinoma (ESCC). Tumor

SLC7A9 expression may serve as a prognostic marker for lymph node metastasis in ESCC patients (<https://doi.org/10.1245/s10434-021-11001-1>).

DISCLOSURE None.

© Society of Surgical Oncology 2021

M. Kanda, MD, PhD, FACS
 e-mail: m-kanda@med.nagoya-u.ac.jp

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.